Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beta Bionics (BBNX) EPS (Weighted Average and Diluted) (2024 - 2025)

Beta Bionics (BBNX) has disclosed EPS (Weighted Average and Diluted) for 2 consecutive years, with -$0.29 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 89.42% to -$0.29 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.94 through Dec 2025, up 77.55% year-over-year, with the annual reading at -$1.81 for FY2025, 78.95% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.29 in Q4 2025 for Beta Bionics, up from -$0.33 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.29 in Q4 2025 to a low of -$2.74 in Q4 2024.